Nanoparticle CAR Expression Compositions for Cell-Specific Immune Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cellular immunotherapy approaches, such as CAR-T cell therapy, face challenges in directing recombinant polynucleic acid expression to specific cell types, leading to non-specific effects and limitations like cytotoxicity, T cell aplasia, poor tumor penetration, and immunosuppressive tumor microenvironment interference.
Innovation Solution
Engineering NK, T, and B cells to express chimeric fusion proteins (CFPs) via recombinant polynucleic acids, encapsulated in nanoparticle delivery vehicles, ensuring targeted expression in specific cell types by utilizing cell-specific transmembrane domains and antigen binding domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant polynucleic acid molecules such as CARs are delivered systemically to treat disease, then therapeutic effect can be achieved, but non-specific expression in unwanted cell types causes harmful effects
Solution Approach 1:
The patent applies local quality by designing cell-type specific polynucleic acid molecules with unique transmembrane domains that are naturally expressed only on the surface of specific cell types (e.g., NK cells, T cells, B cells). This ensures the therapeutic polynucleic acid is delivered and expressed only in the desired target cells, avoiding non-specific effects in other cell types while maintaining therapeutic efficacy.
2Reliability
If CAR-T cells are used to target cancer cells, then cytotoxic response is induced, but T cell aplasia occurs due to prolonged persistence
Solution Approach 1:
The patent employs the principle of using short-lived NK cells instead of long-lived T cells. NK cells have a limited lifespan that prevents prolonged persistence in the body, thereby avoiding the development of T cell aplasia while still providing effective anti-tumor activity during their active period. This trade-off accepts temporary action over long-term persistence to avoid harmful side effects.
3Reliability
If CAR-T cells are administered to treat cancer, then therapeutic effect is achieved, but poor penetration into solid tumors occurs
Solution Approach 1:
The patent applies parameter changes by modifying the characteristics of the cellular immune effectors from T cells to NK cells. NK cells exhibit different migratory and invasive properties compared to T cells, enabling them to better penetrate into solid tumor tissues and reach cancer cells within the tumor microenvironment, thereby improving therapeutic efficacy in solid tumor treatments.
4Reliability
If CAR-T cells are used for immunotherapy, then anti-tumor activity is generated, but function is negatively influenced by immunosuppressive tumor microenvironment
Solution Approach 1:
The patent uses NK cells with short lifespans that do not become permanently exhausted like T cells. NK cells can rapidly respond to tumor antigens and revert to a quiescent state after their brief functional period, avoiding the chronic immunosuppression and exhaustion that plague CAR-T cell therapy in the tumor microenvironment.
Data Source
AI summary
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.